FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis Approved for once-daily treatment in mild, moderate, and severe plaque psoriasis with no limitations on duration of use Established efficacy – provides rapid clearance of plaques and reduction of itch in all affected areas of the body Safe and very well-tolerated, steroid-free cream with minimal application site reactions Commercial product expected to be available by mid-August Management will host conference call on Monday, August 1 at 8:30 a.m. EDT

Continue ReadingFDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older